RE:RE:RE:RE:RE:RE:Full report from Doug LoeYou can have cancer cells at different stages of evolution within a tumor, but you won't have differences of stages between tumors in a same patient. Since cancer is an evolving disease with genetic mutations happening along the way, advanced cancers are by definition genetically heterogenous. Genetic heterogenicity means heterogenicity in protein expression (receptors, enzymes, etc...)
Wino115 wrote: Good point. I think your approach is right. In case someone doesn't have that old R& D day presentation, here's the slide. I actually don't recall if this is the level of overexpression of Sortilin or is the percent of tumors in these cancers that overexpress Sortilin at what they consider a "high" level. Maybe JFM can recall what they mean here.
Treatment of Sortilin Positive Cancers
Sortilin expression in cancers
• Associated with ovarian and breast cancers aggressiveness:
-
90-100% of ovarian cancers
-
79% of invasive ductal breast cancer (60% in TNBC)
-
Increased expression as a function tumor grade (I to IV)
• Other cancers expressing Sortilin:
-
Endometrial (90%)
-
Lung (65%)
-
Melanoma (90-100%)
-
Urothelial (70%)
-
Colorectal (30%)
-
Pancreatic (30%)